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Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) in HIV infected individuals is a serious threat to global
efforts to combat tuberculosis. Inconsistent findings on the association between HIV infection and MDR-TB were
present in many studies. We aimed to review existing data on the relationship between HIV infection and MDR-TB
systematically to assess the contribution of HIV on MDR-TB worldwide. We also investigated the patterns of MDR-TB
by age, country-wise income, study designs, and global regions.
Methods: We utilized PubMed, Google Scholar, and ScienceDirect databases to select eligible studies for meta-
analysis that were published between January 1, 2010, and July 30, 2020. The random-effects model was used to
obtain the pooled odds ratio of the crude association between HIV and MDR-TB with a 95% confidence interval.
We investigated the potential publication-bias by checking funnel plot asymmetry and using the Egger’s test.
Moreover, we assessed the heterogeneity using the I2 statistic. Sensitivity analysis was performed based on sample
size and adjustment factors. The protocol was registered with PROSPERO-CRD42019132752.
Results: We identified 1603 studies through a database search, and after subsequent eliminations we selected 54
studies including 430,534 TB patients. The pooled odds of MDR-TB was 1.42 times higher in HIV-positive patients
than HIV-negative patients (OR=1.42,CI=1.17–1.71, I2=75.8%). Subgroup analysis revealed that the estimated pooled
odds for South-East Asian countries was 1.86, which is the highest in WHO regions (OR=1.86,CI=1.30–2.67, I2=
0.00%), followed by Europe and Africa. The effect estimate was found to be higher for primary MDR-TB (OR=2.76,
CI=1.70–4.46, I2=0.00%). There was also a trend towards increased odds of MDR-TB for HIV patients older than 40
years (OR=1.56,CI=1.17–2.06). The association was found to be significant in high-burden TB countries (OR=1.75, CI=
1.39–2.19) and in high-income countries (OR=1.55, CI=1.06–2.27).
Conclusion: Such findings indicate that HIV infection raises the risk of MDR-TB, and after contrasting it with the
results of the earlier pooled study, it appeared to be an upward risk trend. Moreover, we found that the risk is the
highest in the South-East Asian region. A balanced allocation of resources is needed to halt both primary and
secondary MDR-TB, particularly in HIV infected people with 40 years of age and older.
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Background
Tuberculosis is a global public health problem caus-
ing illness among millions each year. In 2018, there
were an estimated 10 million new TB cases, and 8.6%
were living with HIV [1]. The care and control of tu-
berculosis are threatened by the emergence and amp-
lification of multi-drug resistant tuberculosis (MDR-
TB). It was declared as a public health crisis by
WHO in 2013 [2]. Globally, there were an estimated
484,000 incident cases of MDR/Rifampicin-resistant
tuberculosis (RR-TB). Of them, about 39% (186772)
were notified, and 32% (156071) enrolled for treat-
ment in 2018 [1]. The large gap in diagnosis and
treatment increases the likelihood of transmission of
TB plus MDR-TB [3]. Poor TB treatment outcome is
also reported in TB-HIV co-infected patients, which
further ignites MDR-TB development [4–6]. A WHO
report shows that 3.4% of new cases and 18% of pre-
viously treated TB cases are estimated to have MDR/
RR-TB [1]. However, HIV positive individuals are 20
times more likely to develop active TB than those
without HIV [7]. Despite enormous concerted mea-
sures taken to control tuberculosis and reduce HIV-
associated deaths, it ranks among the top ten causes
of death worldwide [1]. About 0.25 million deaths
were attributed to TB associated with HIV, and nearly
15% of all global tuberculosis deaths were contributed
by MDR-TB in 2018 [1].
Drug-resistant tuberculosis (DR-TB) is defined as a
case of one or more anti-TB drugs resistant to bacteria
that cause TB. There are various forms of DR-TB:
mono-drug-resistant TB (mono-DR-TB), polydrug-
resistant TB (poly-DR-TB), rifampicin-resistant TB
(RR-TB), multidrug-resistant TB (MDR-TB), and exten-
sively drug-resistant TB (XDR-TB). MDR-TB is a form
of TB that does not respond to at least isoniazid and ri-
fampicin, the two most potent anti-TB drugs. The
XDR-TB is also a form of MDR-TB resistant to isonia-
zid and rifampicin, plus any fluoroquinolone and at
least one of three injectable second-line drugs (i.e., ami-
kacin, kanamycin, or capreomycin). RR-TB is classified
as a case of TB, which shows either rifampicin (R) re-
sistance only or accompanied by resistance to other
anti-TB drugs in different forms. About half a million
people worldwide acquired MDR-TB in 2017, and a
further 161,000 people with RR-resistant TB were
newly diagnosed with MDR-TB [1]. China, India, and
Russia were the countries with the largest number of
MDR / RR-TB cases (47% of the global total). Approxi-
mately 6.2% of these cases were XDR-TB [1].
Global tuberculosis burden study 2015 suggests taking
the necessary steps to prevent HIV for reducing the bur-
den of tuberculosis [8]. Estimates reveal that around 1.7
billion of the world’s population has latent tuberculosis
infection [1]. Of them, 5–15% of cases are at risk of devel-
oping active diseases during their lifetime, and people liv-
ing with HIV have a higher risk of falling ill [9, 10].
Alarmingly, it appeared from a mathematical model that
there were approximately 19 million people globally with
latent MDR tuberculosis infection (10% were at risk of ac-
tive disease) in 2015 [11]. Undoubtedly, latency is affected
by HIV infection and is one of the most potent risk factors
for converting into active disease, drug-susceptible, or
drug-resistance [10–12].
The surge of MDR-TB occurrence in HIV-prevalent
settings is of great public health importance. An up-
dated understanding of the magnitude of association is
needed with the accumulation of recent evidence that
supports a positive association between HIV and MDR-
TB [13, 14]. Additionally, two systematic reviews re-
vealed an increased risk of transmission-associated
MDR-TB (primary) among HIV positive individuals
[15, 16]. Mesfin et al. conducted the latest systematic
review and meta-analysis on the relationship between
HIV infection and MDR-TB in 2014, which included
research from 1994 to 2011. Even after the latest meta-
analysis, conflicting results on the association were
found in numerous studies conducted during the last
decade. The objective was to provide an up-to-date
pooled risk estimate on the relationship between HIV
infection and MDR-TB growth and compare the risk
pattern of MDR-TB with previous systematic reviews.
Methods
Search strategy
We researched on PubMed, Google Scholar, and Sci-
ence Direct databases to select eligible peer-reviewed
articles for our systematic review and meta-analysis.
Relevant observational studies (cross-sectional, case-
control, and cohort) were screened to assess the asso-
ciation between HIV infection and MDR-TB, pub-
lished from January 1, 2010, to July 30, 2020 (date of
the last search). The screening language was restricted
to English. The particular keywords used for search-
ing articles were “Multidrug-resistant tuberculosis” or
“MDR-TB” or “Drug-resistant TB” or “Risk factors of
MDR-TB” or “Predictors of MDR-TB” and “HIV” or
“Human Immunodeficiency Virus”. A summary of
search terms is provided in Appendix A. Search re-
sults were compiled using a citation management
software Zotero. In addition to databases used, we ex-
plored references of selected studies to incorporate all
potential pertinent articles to construct our summary
estimates. The study adheres to the Preferred Report-
ing Items for Systematic Review and meta-analysis
(PRISMA) guidelines [17]. The protocol was regis-
tered in the PROSPERO database-CRD42019132752.
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Selection criteria
The primary outcome of the meta-analysis was an un-
adjusted odds ratio exhibiting the crude association
between HIV infection and MDR-TB. The articles
that reported or provided adequate data to calculate
the frequency of MDR-TB and non-MDR-TB, subdi-
vided by HIV status (positive or negative), were in-
cluded in our systematic review. We included studies
where MDR-TB is the outcome of interest. We contacted
the author for the insufficient information given in any
study. If the author didn’t reply, we excluded the article.
To be eligible for inclusion, any drug susceptibility testing
method (culture on solid and/or liquid media, molecular
techniques, clinical records, Table 1) were accepted for the
diagnosis of multidrug-resistant tuberculosis (Mycobacter-
ium tuberculosis strain resistant at least to rifampicin and
isoniazid). The comparison group (non-MDR-TB) con-
sisted of drug-susceptible tuberculosis patients and/or re-
sistant to any single drug. HIV status was ascertained by
HIV test reports, clinical/hospital records, databases/regis-
ters, or directly from patients. Studies reported on non-
tuberculous mycobacterium, case reports, case studies, sys-
tematic review, meta-analysis, a duplicate publication of
the same study, and studies with only abstract were ex-
cluded. We also didn’t include grey literature (theses and
dissertations). Studies with less than three HIV/MDR-TB
participants were excluded because these studies cause the
analysis to be heterogeneous. Titles and abstracts of the
studies obtained from database searches were screened in-
dependently by two reviewers ZZS and FH. Full text of po-
tential articles was further reviewed for eligibility regardless
of the study base (hospital or population). Articles might
have been eliminated for more than one rationale. Any dis-
agreements were discussed with senior authors (JB or AH)
until a consensus was reached or by the arbitration of AH
alone.
Data extraction
A pre-specified and standardized form was used for
data abstraction. For the estimation of the crude odds
ratios, key data on the number of MDR-TB HIV posi-
tive, number of MDR-TB HIV negative, number of
non-MDR-TB HIV positive, and number of non-
MDR-TB HIV negative patients were extracted from
each study. Additionally, data on the name of the first
author, country, year of publication, years of recruit-
ment, study design (cross-sectional, case-control or
cohort), source of data (hospital/medical records, lab
reports, database/register, or direct from the patients),
methods carried out to determine drug resistance pat-
tern, number of enrolled TB patients, the mean or
median age of the MDR-TB cases, proportion of male
patients among MDR-TB cases (%), type of MDR-TB
(primary, secondary or both), form of tuberculosis
(pulmonary, both pulmonary and extra-pulmonary or
not defined), and proportion of the patients with
extra-pulmonary tuberculosis among MDR-TB cases
(%) were entered in the spreadsheet. We further
stratified the articles based on global regions (defined
by World Health Organization) income level (World
Bank classification by income, GNI per capita) and
burden for MDR-TB (list used by WHO 2016–2020)
of the countries [1, 72]. Data abstraction from indi-
vidual studies was executed by two trios of investiga-
tors (AI, JB & ZZS and HRK, DHH & FH), from
March 2019 to June 2020. The presence of any incon-
sistency in data extraction was verified by a seventh
investigator (AH).
Quality assessment
Two trios of investigators (AI, JB & ZZS and HRK,
DHH & FH) scored each study to ascertain methodo-
logical quality independently. The corresponding au-
thor (AH) subsequently examined all the assessments.
Furthermore, contentions aroused in the course of
quality scoring were resolved through discussions be-
tween investigators. It was evaluated using the
Newcastle-Ottawa Scale (NOS). It consists of three
domains: selection, comparability, and exposure or
outcome of interest. Few points on the NOS related
to appropriate methods for evaluating exposure vari-
ables and outcomes were designed for the relevance
to our research question (Supplementary file 1). Two
outcome groups were considered comparable if the
HIV status was adjusted for the previous history of
diagnosis with tuberculosis and/or any other sociode-
mographic variable (e.g., age, sex, etc.). These studies
also reflect high or medium NOS scores (Supplemen-
tary file 2). Articles were given scores to reflect meth-
odological stringency, lucidity, and transparency in
reporting. Nevertheless, we did not exclude any arti-
cles based on quality scoring. It may exclude studies
coming from resource-limited settings. Therefore, we
did not provide insight into this particular cluster of
studies. Moreover, the PRISMA statement consists of
a checklist of 27 items and is given in Supplementary
file 3.
Statistical analysis
We performed data analysis using meta and metafor
packages in the R statistical software (version 3.5.1).
We calculated crude odds ratio with a 95% confi-
dence interval (CI) for individual study from the ab-
stracted frequencies (numerators and denominators).
After that, we estimated the pooled odds ratio (over-
all) using the random-effects model, allowing the true
effect size to vary from study to study. The summary
estimate (OR) for the association between HIV
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Table 1 Characteristics of the included studies in the meta-analysis (according to the order of year)



























































Burkina Faso 316 42 87.66 NA NA NA 1o,2o 85.71
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Malaysia 314 105 66.70 51 PTB NA 1o,2o 50.50
Sultana et al. BMC Infectious Diseases           (2021) 21:51 Page 4 of 13
Table 1 Characteristics of the included studies in the meta-analysis (according to the order of year) (Continued)
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Assefa et al. [54] 2017 Case-
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Chan et al. [69] 2020 Surveillance 2011–
2016












Canada 402 46 47.8 ~ 45 PTB,
EPTB
26.08 1o,2o 34.80
MDR-TB Multidrug-resistant tuberculosis, PTB Pulmonary tuberculosis, EPTB Extra-pulmonary tuberculosis, PTC Previously treated cases
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infection and MDR-TB were reported with 95% CI.
The calculated odds ratio of each study and the com-
bined effect estimate with 95% CI were graphically
represented by forest plots. Publication bias was
assessed by observing the symmetry of funnel plots
visually. Further confirmation was conducted using
Egger’s test (weighted regression with multiplicative
dispersion model), while the p-value < 0.10 was sug-
gestive of statistical significance. Heterogeneity across
the selected studies was assessed by I2 statistic (> 75%
signifies substantial, 50–75% moderate and 25–50%
low heterogeneity). The I2 statistic represents the per-
centage of total variation across studies due to het-
erogeneity rather than chance. We also conducted a
sensitivity analysis that removed the study contribut-
ing to the highest weight to evaluate the robustness
of the findings.
Analysis of the subgroups was carried out to deter-
mine the pooled odds ratio for each group and to
look for potential explanations of the heterogeneity.
Pre-determined subgroups were WHO global regions
(Africa, Europe, South-east Asia, America, Pacific, and
Eastern Mediterranean), the income level of the coun-
try (high, upper-middle, lower-middle and low), the
burden for MDR-TB on the country (high and low),
design of the study (cross-sectional, case-control and
cohort), type of MDR-TB (primary, secondary and
both), mean or median age 40 years and older, and
diagnostic method used for MDR-TB (culture and
culture and/or molecular technique). Funnel plot
asymmetry and egger’s tests were done to assess the
presence of publication bias in each subgroup.
Results
Our systematic review identified 1603 studies
through a database search. After eliminating the du-
plicates, titles and abstracts of 1188 articles were
scanned by the investigators to retrieve a set of rele-
vant studies for further review. We subsequently nar-
rowed down to 145 possible studies, and three were
added for full-text evaluation through manual search
from the reference lists of included studies. Finally,
54 studies were selected in our systematic review and
meta-analysis, including 430,534 TB patients (Fig. 1).
The characteristics of the selected studies can be
found in Table 1.
(*Studies were excluded because of more than one ra-
tionale and the references of excluded studies are given
in Supplementary file 4.)
The retrieved articles represented 36 countries
from all WHO global regions (Africa, Europe, South-
east Asia, America, Pacific, and Eastern Mediterra-
nean). Of the 54 studies, three were conducted in
multiple centers in different countries (Table 1).
Nearly half of studies were reported from the Afri-
can region. Many of the studies were performed in
Ethiopia and from high MDR-TB burden countries.
The systematic review included 20 case-control
studies and 31 studies considering tuberculosis as a
pulmonary form. Of the 54 studies, 42 investigated
both primary and secondary MDR-TB. The propor-
tion of MDR-TB cases with extra-pulmonary tubercu-
losis varied from 2 to 36.36%. The proportion of
previously treated tuberculosis among multidrug-
resistant cases ranged from 12.00 to 99.11% (39 stud-
ies). It shows from Table 1 that only culture-
confirmed MDR-TB cases were reported in 37 of the
studies.
It appears from Fig. 2 that the overall pooled odds
ratio is 1.42 (95% CI= 1.17–1.71), which suggests
that the odds of developing MDR-TB in HIV-
infected patients was 42% higher than those of HIV-
negative individuals. The evidence of publication bias
was tested by visual examination of funnel plot sym-
metry, and further, the absence of the publication
bias was supported by the Egger test (p=0.36) and is
shown in Fig. 3.
For the South-East Asian countries, the pooled odds
of MDR-TB was 1.86 times higher for HIV positives
than HIV negative individuals (OR=1.86, 95% CI=
1.30–2.67). Most studies obtained from the African
region had a pooled odds ratio of 1.41 (95% CI=
1.06–1.89). Results from WHO regions indicate that
MDR-TB among HIV-persons is more in South-East
Asian countries compared to other regions. The
pooled ORs show lower odds of developing MDR-TB
among HIV patients in upper-middle-income coun-
tries (OR=1.26, 95% CI=0.86–1.86) and low-income
countries (OR=1.40, 95% CI=0.99–1.98) compared to
high-income countries. The pooled odds ratio in the
high TB-burden countries (OR=1.75, 95% CI= 1.39–
2.19) was found to be significantly higher compared
to the low TB-burden countries (OR=1.0, 95% CI=
0.72–1.39).
Findings from subgroup analysis in Table 2 shows
the pooled odds ratio of the cross-sectional studies
was 1.53 (95% CI= 1.20–1.96). Cohort studies pro-
vides odds ratio of 1.33 (95% CI=1.09–1.62), and
case-control studies provides odds ratio of 1.22 (95%
CI=0.87–1.71). Cross-sectional studies contribute
about 70% of the weight of the overall meta-analysis
research. For primary MDR-TB, the estimate was
higher than secondary MDR-TB (OR=2.76, 95% CI=
1.70–4.46) with no heterogeneity among the studies.
The majority of studies included both primary and
secondary MDR-TB (42 studies), and subgroup ana-
lysis reveals that the odds of developing both primary
and secondary MDR-TB in people infected with HIV
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were 1.42 times more compared to the individuals
without HIV (OR=1.42, 95% CI= 1.16–1.74). Further-
more, the trend towards the development of MDR-TB
in HIV-positive people increased with age (i.e., mean
or median age of cases 40 years and older, OR=1.56,
95% CI= 1.17–2.06, and for below 40 years of age is
OR=1.45, 95% CI= 1.11–1.91). In HIV infected pa-
tients, the pooled odds ratio of culturally confirmed
MDR-TB cases (OR=1.52, 95% CI=1.20–1.93) was
slightly higher than the mixed (i.e., culture and
molecular technique) (OR=1.30, 95% CI=0.93–1.81).
Only one study (OR=1.27, 95% CI= 0.6–2.17) consid-
ered the diagnosis of MDR-TB by molecular
technique.
Sensitivity analysis
We conducted sensitivity analyses that excluded each of
the following types of studies: studies with fewer than
1000 participants; studies from countries in Africa; and
studies published in 2015 or earlier. Forest plots are
Fig. 1 PRISMA flow diagram for Study selection
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reported in Supplementary file 5. When considering
studies of more than 1000 participants, the OR of MDR-
TB among HIV infected individuals tends to be 1.41
(OR=1.41, CI=1.13–1.76). The OR is 1.38 (CI=1.01–
1.88) considering studies published after 2015. The OR
is also 1.46 when studies outside African studies (OR=
1.46, CI=1.14–1.87) are considered. The findings are,
therefore, similar to the meta-analysis with 54 studies.
Discussion
About half a million TB patients were included from
54 studies in our systematic review and meta-
analysis. Based on the findings of this meta-analysis,
the odds of MDR-TB among HIV-positive cases were
1.42 times higher, and this was statistically signifi-
cant. An earlier pooled study by Mesfin et al. (OR=
1.24, 95% CI= 1.04–1.43) included 24 studies pub-
lished from 1994 to 2011, and our finding appears
to indicate an upward trend of odds ratio after being
compared to it. Moreover, the 18 cross-sectional
studies from Mesfin et al. gave pooled effect esti-
mate for MDR- TB and HIV was 1.26 (OR=1.26,
95% CI= 1.02–1.49) while the result from our meta-
analysis (30 studies) is 1.55 (OR=1.55, 95% CI=
1.26–1.95). Another meta-analysis (1988–2007) did
not report a pooled effect estimate due to high het-
erogeneity among the studies [15]. Comparing with
Mesfin et al. meta-analysis, it suggests over the last
10 years that people diagnosed with HIV are more
likely to have MDR-TB.
Subgroup analysis by the WHO global regions re-
veals that the OR of South-East Asia was found the
highest, followed by Europe and Africa. The WHO
South-East Asia region is a home for a quarter of
the world ‘s population, with a 44% TB burden, and
the second-highest HIV prevalence [1]. Additionally,
one-third of the global MDR-TB lies in this region
[1]. In Europe, the proportion of MDR-TB among
HIV-infected people increased sharply between 2008
and 2017, from 3 to 12%. The aforementioned data
ratifies how our results reflect a major risk of MDR-
TB among HIV patients.
Furthermore, the estimated pooled OR was found
to be significant for the high TB burden countries.
In our meta-analysis, with the age of 40 years and
older, the pooled odds ratio of developing MDR-TB
among HIV infected individuals continues to in-
crease significantly. Findings from the subgroup
study also showed that the pooled odds ratio of the
cross-sectional studies was higher than that of the
Fig. 2 Forest plot exhibiting OR of each study and combined OR of the crude association between HIV infection and MDR-TB
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cohort studies. Similar findings were also seen in the
previous meta-analysis [16].
Another notable finding was the significant asso-
ciation between HIV infection and primary MDR-
TB. This finding corresponds to the previous two
systematic reviews [15, 16]. In many instances,
despite being infected primarily with drug-resistant
strains and subsequent development of MDR-TB
(primary), it will initially be reported as drug-
susceptible tuberculosis. Drug susceptibility test is
not routinely done in some settings and performed
only after the failure of initial treatment, which
will normally be classified as secondary MDR-TB
[73]. We found an insignificant pooled odds ratio
between HIV and MDR-TB in low-income coun-
tries, especially in Africa. It highlights the need to
develop effective drug-resistance diagnosis in many
resource-limited settings. Among the high-income
countries, the combined estimate was found higher
than that of the low-income countries. It is im-
portant to gain a clear understanding of these
mechanisms to build effective strategies to control
the expansion of MDR-TB in HIV patients.
In our systematic review, we found most studies
considered the diagnosis of MDR-TB as a phenotypic
approach that confirmed by culture. The pooled
odds ratio of MDR-TB was considerably higher for
studies when a diagnosis for MDR-TB was made by
culture-confirmed than the mixed or molecular
technique. Such culture-confirmed traditional ap-
proaches take months to confirm the diagnosis of
MDR-TB and ultimately lead to delay in treatment,
increased transmission, and poor outcome [74].
However, it should also be noted that the diagnosis
of tuberculosis in patients infected with HIV is diffi-
cult due to reduced bacterial load and cavitation, as
well as poor performance of the standard diagnostic
tools [75–77]. Additionally, HIV-associated super-
infection may be a motivating factor for drug-
susceptible conversion to resistant tuberculosis [78].
Research also shows that multiple tuberculosis strain
infections frequently interfere in HIV patients [79,
80]. It may also show misleading phenotypic drug-
resistance diagnosis [81]. As such, the extent of
spread when confirming MDR-TB by a traditional
method is far more deadly than is illustrated, espe-
cially in HIV-endemic settings.
We acknowledge that our systematic review and
meta-analysis has limitations. There was dispropor-
tionate allocation of studies among the six WHO re-
gions. Additionally, the included studies were mostly
from Africa (i.e., 25 of 54 studies from Africa).
Moreover, the largest nation, China, is not included
in the study. Besides, the database search language
was restricted to English. Therefore, the above limi-
tations might curb the generalizability of our find-
ings. Moreover, substantial heterogeneity was
observed between the studies, although it was
Fig. 3 The funnel plot reveals existence of publication bias though most points fall within the 95% confidence region. Each point represents a
study; the y-axis represents standard error, and the x-axis displays the ratio of the log odds of the study
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expected to be from the differences in MDR-TB and
HIV ascertainment, study design, and data collection
methods between the selected studies. Mild or no
heterogeneity was also observed in a different sub-
group analysis. We included only the observational
studies which are susceptible to selection bias.
Conclusion
The meta-analysis clearly shows a growing trend in
MDR-TB risk among HIV-infected people. Balanced re-
source allocation for Asian, European and African coun-
tries should be considered to halt both primary and
secondary MDR-TB, especially among those with in-
creasing age. As such, the enhancement of the diagnosis
and proper overall management of MDR-TB among
HIV-positive individuals has become crucial in achieving
WHO’s goals of ‘End TB’ by 2035.
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Table 2 Summary results of subgroup analysis
Subgroup No of studies (TB patients) Summary OR 95% CI I2 (%) p-value*
WHO Region
South-East Asia 6 (1947) 1.86 1.30–2.67 0.00 0.07
Europe 11 (154031) 1.79 1.42–2.27 52.90 0.01
Eastern Mediterranean 1 (634) 0.44 0.15–1.31 – –
Africa 25 (14723) 1.41 1.06–1.89 76.65 0.53
America 6 (256640) 1.17 0.75–1.84 74.15 0.98
Western Pacific 4 (2559) 1.11 0.32–3.89 82.89 0.97
TB Burden countries
Low 18 1.0 0.72–1.39 63.91 0.71
High 30 1.75 1.39–2.19 76.68 0.09
Countries by income level
High 7 1.55 1.06–2.27 50.85 0.09
Upper-middle 14 1.26 0.86–1.86 87.0 0.85
Low-middle 11 1.66 1.23–2.26 43.91 0.31
Low 19 1.40 0.99–1.98 78.44 0.97
Study design
Cross-sectionala 30 1.53 1.20–1.96 71.6 0.27
Case-control 20 1.22 0.87–1.71 75.77 0.26
Cohort 4 1.33 1.09–1.62 0.00 0.20
Outcome MDR-TB type
Primary 4 2.76 1.70–4.46 0.00 0.87
Both 42 1.42 1.16–1.74 80.63 0.50
Secondary 8 1.08 0.64–1.82 76.26 0.18
Mean/Median Age (MDR-TB)
> 40 15 1.56 1.17–2.06 71.66 0.57
<=40 32 1.45 1.11–1.91 78.85 0.09
Diagnosis of MDR-TB by
Culture 37 1.52 1.20–1.93 80.56 0.40
Mixed 14 1.30 0.93–1.81 76.97 0.48
Molecular technique 1 1.27 0.6–2.17 – –
Overall 54 1.42 1.17–1.71 75.8 0.36
MDR-TB Multidrug resistant tuberculosis, HIV Human Immunodeficiency Virus, CI Confidence Interval
a two surveillance were included into cross-sectional studies
* p value for Egger’s test for publication bias
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Additional file 4. References of studies excluded after full-text review.
Additional file 5. Sensitivity analysis.
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